Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 3: Pre- and postprocedural pain level assessment^{^a}
No. of Patients
Primary outcomes 
 >50% pain relief at 15 min 185 (75.2%)
 <50% pain relief at 15 min 61 (24.8%)
 >50% pain reduction from baseline at 2 wk 165 (67.1%)
 <50% pain reduction from baseline at 2 wk 81 (32.9%)
 No preprocedural pain (patient-reported numbness or paresthesia) 8 (3.1%)
 Alleviation of preprocedural numbness or paresthesia at 2 wk 7 of 8 (87.5%)
Minor adverse reactions or events 
 Vasovagal reaction 3 (1.2%)
 Transient pseudo-Horner syndrome (sympathetic blockade) 1 (0.4%)
 New onset of diffuse headache 2 (0.8%)
 Increase in usual pain in a familiar distribution 8 (3.1%)
↵a Transient arm numbness postinjection was not included as an untoward effect because it is expected when exposing cervical nerve roots to a lidocaine containing mixture.

	No. of Patients
Primary outcomes
>50% pain relief at 15 min	185 (75.2%)
<50% pain relief at 15 min	61 (24.8%)
>50% pain reduction from baseline at 2 wk	165 (67.1%)
<50% pain reduction from baseline at 2 wk	81 (32.9%)
No preprocedural pain (patient-reported numbness or paresthesia)	8 (3.1%)
Alleviation of preprocedural numbness or paresthesia at 2 wk	7 of 8 (87.5%)
Minor adverse reactions or events
Vasovagal reaction	3 (1.2%)
Transient pseudo-Horner syndrome (sympathetic blockade)	1 (0.4%)
New onset of diffuse headache	2 (0.8%)
Increase in usual pain in a familiar distribution	8 (3.1%)